Scott Kopetz, MD, PhD, FACP
The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer (CRC) to include the regimen of encorafenib (Braftovi) and binimetinib (Mektovi) plus EGFR inhibition with either cetuximab (Erbitux) or panitumumab (Vectibix) as a Category 2a treatment recommendation for patients with BRAF
V600E–mutant metastatic colorectal cancer (CRC), after failure of 1 or 2 lines of therapy for metastatic disease.
Array BioPharma Inc, the manufacturer of encorafenib and binimetinib, reported in a press release that the NCCN based its recommendation on data from the BEACON CRC trial. Data reported at the 2019 Gastrointestinal Cancers Symposium from the safety lead-in (SLI) phase of the trial showed that clinical outcomes with the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and cetuximab exceeded historic data in patients with BRAF
V600E-mutant metastatic CRC.
Results from 30 patients showed an estimated median progression-free survival (PFS) of 8.0 months and an estimated median overall survival (OS) of 15.3 months with a median duration of follow-up of 18.2 months. The overall response rate (ORR) was 48% by local assessment, with 3 patients achieving a complete response (CR).
... to read the full story